Trial Profile
A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs AC 150 (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Aciex Therapeutics
- 22 Apr 2014 New trial record